Sign inJoin waitlistJoin the waitlist

James Kochenderfer

Investigator, Experimental Transplantation and Immunology · University of Pennsylvania Health System

Credentials: · ·

History

University of Pennsylvania Health System
Present

University of Texas M D Anderson Cancer Center
1998–2001
University
West Virginia University School of Medicine
1994–1998

Research

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
The Lancet · 2015 · 2,436 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · Last of 23 authors · 1,419 citations
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen…
Journal of Clinical Oncology · 2015 · First of 26 authors · 1,324 citations

Steven Rosenberg
26 papers · 8 as a fellow
JB
Jennifer Brudno
24 papers · 3 as a fellow
RG
Ronald Gress
11 papers
David Stroncek
10 papers
James Yang
10 papers
Lekha Mikkilineni
10 papers · 3 as a fellow
Irina Maric
8 papers
Constance Yuan
7 papers
MS
Maryalice Stetler-Stevenson
7 papers
Stephanie Goff
7 papers · 1 as a resident
Terry Fry
7 papers
Crystal Mackall
6 papers

Grants

Development of Chimeric Antigen Receptors Targeting Multiple Myeloma
National Cancer Institute · ZIA
Contact PI · $9.5M · Division of Basic Sciences - Nci
Improved Chimeric Antigen Receptor Therapies B-Cell Malignancies
National Cancer Institute · ZIA
Contact PI · $8.3M · Division of Basic Sciences - Nci
Development of CAR T Cells Targeting T-Cell Malignancies
National Cancer Institute · ZIA
Contact PI · $2.3M · Division of Basic Sciences - Nci
Adoptive T-Cell Therapies Targeting Mutations in Hematologic Malignancies
National Cancer Institute · ZIA
Contact PI · $2.1M · Division of Basic Sciences - Nci

Clinical trials

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2029
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2024–2030
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2023–2029
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2019–2021